General Information
The Retina Institute participates in numerous national studies recognizing that medical research lies at the core of clinical advancements. These studies are used to assist in the diagnosis, prevention and treatment of various retinal diseases. Clinical trials help establish if new treatments, new drugs, or new surgical procedures are safe and effective.
Participation in a clinical trial is an important decision and should be discussed with a physician. Enrollment in a study possibly means receiving the newest management and care for a disease or illness. Participants often join to help others with the same condition by assisting researchers in their efforts to find better treatments. These trials offer future hope for many people with sight-threatening conditions.
Clinical trials in the U.S. must follow strict protocol and be registered with The National Institute of Health (NIH). A listing of these studies can be found in the clinicaltrials.gov database.
ACHIEVE
Pathology: Wet AMD
Description: A Phase 3b Study of Surabgene Lomparvovec Assessing the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity in a Real-World Context
AMGEN
Pathology: nAMD
Description: A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration
CAPRI
Pathology: Diabetic Macular Edema
Description: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME
CLOVER
Pathology: Dry AMD
Description: AMD progression study – standard of care follow-up visits with collection of saliva for genetic analysis
CTX203
Pathology: Dry AMD
Description: A novel, first-in-class apolipoprotein mimetic peptide developed by (Character Biosciences) to treat high-risk intermediate Dry Age-Related Macular Degeneration (AMD)
DRCR AF
Pathology: Diabetic Retinopathy
Description: A randomized trial evaluating Fenofibrate for prevention of diabetic retinopathy worsening
DRCR AL
Pathology: Radiation Retinopathy
Description: A randomized clinical trial evaluating intravitreal Faricimab injections or Fluocinolone Acetonide intravitreal implants vs. observation for prevention of visual acuity due to radiation retinopathy
DRCR AM
Pathology: Epiretinal Membranes
Description: A randomized trial comparing immediate versus deferred surgery for symptomatic epiretinal membranes
DRCR AP
Pathology: Proliferative Diabetic Retinopathy
Description: A randomized clinical trial evaluating combination Faricimab + PRP versus vitrectomy + endolaser for treatment of proliferative diabetic retinopathy
ECLIPSE
Pathology: Diabetic Macular Edema
Description: A randomized, controlled, subject and evaluator-masked, phase 2, clinical trial comparing EC-104 intravitreal implant to Ozurdex for the treatment of diabetic macular edema
IHEEZO IST
Pathology: Any patients receiving intravitreal injections
Description: Comparing intravitreal injection pain scores using Iheezo (Chloroprocaine HCl ophthalmic gel 3%) versus subconjunctival Lidocaine (2%): A randomized, controlled trial
ONL1204
Pathology: Geographic Atrophy
Description: A Phase 2 Multicenter, Randomized, Double-masked, Sham-controlled, Reference-arm Study to Evaluate Efficacy and Safety of ONL1204 in Patients with Geographic Atrophy (GA) associated with Age-related Macular Degeneration (AMD)
OPREGEN
Pathology: Geographic Atrophy
Description: Non-Randomized, Open-Labeled Study following safety monitor team for surgical development changes in each cohort involving subretinal injection of stem cells for fovea involved geographic atrophy
OTX-TKI-2023
Pathology: nAMD
Description: A phase 3, multicenter, double-masked, randomized, parallel-group study to evaluate the efficacy and safety of intravitreal OTX-TKI (axitinib implant) in subjects with neovascular age-related macular degeneration
PEAK & PINNACLE
Pathology: Macular Edema Secondary to Inflammation
Description: A randomized, double-masked, sham-controlled, multicenter, phase 3 study to evaluate the efficacy and safety of intravitreal Tabirafusp Alfa (KSI-101) in participants with macular edema secondary to inflammation
SIENNA
Pathology: Geography Atrophy
Description: A phase 3 study investigating the use of experimental drugs pozelimab and cemdisiran for treating geographic atrophy (GA)
SOL-X
Pathology: nAMD
Description: A phase 3b, Multicenter, Open-Label, Extension Study to Evaluate Long-Term Safety of Intravitreal OTX-TKI (Axitinib Implant) in Participants with Neovascular Age-Related Macular Degeneration Who Successfully Completed 2-Year OT-TKO-2023-AMD-301 or OTX-TKI-2023-AMD-303 Study.